CDK2 and glioblastoma: In GBM, METTL3 targets ADAR1 through a novel molecular pathway, METTL3/ADAR1/CDK2, resulting in the overexpression of the ADAR1 protein, which promotes GBM progression independently of its editing mechanisms [90].